Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience.

ABSTRACT: During past years, the increasing knowledge of molecular mechanisms of inflammatory bowel disease (IBD) have led to the development of several targeted biological therapies. This great expansion of available medical options has prompted the need for comparative data between drugs. For years, given that most randomized controlled trials (RCTs) were performed only versus placebo, this demand has clashed with the absence of head-to-head trials comparing two or more treatments. The quality of evidence coming from real-world experience was low overall, so it was extremely difficult to clarify the correct positioning of the biologicals inside the therapeutic algorithms for IBD. Fortunately, times are changing: head-to-head comparative RCTs have been conducted or are ongoing, and the metho

SUBMITTER: Macaluso FS 

PROVIDER: S-EPMC8111554 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature